This message contains images. If you don't see images, click here to view.
Advertise in this news brief.

Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           March 11, 2015

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store


Factors used for prognosis in advanced cervical cancer
Cancer Network
A new study yielded nomograms for the assessment of locally advanced cervical cancer. These tools included prognostic factors such as histology, performance status, and others. The researchers retrospectively reviewed 2,042 patients with locally advanced cervical carcinoma who were enrolled in GOG clinical trials of concurrent cisplatin-based chemotherapy and radiotherapy. Nomograms were created for 2-year progression-free survival (PFS), 5-year overall survival (OS), and pelvic recurrence. Results were published online ahead of print on March 2 in the Journal of Clinical Oncology.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Special Interest Session VI: SGO Latin America Symposium — March 30
Learn about relevant topics in gynecologic oncology in Latin America and options for collaboration during Special Interest Session VI: SGO Latin America Symposium – The Current, Present & Future of Gynecologic Oncology in Developing Countries-A Call for Future Partnerships on Monday, March 30, from 4:00 p.m. to 7:00 p.m. at the Hilton Chicago during the SGO Annual Meeting.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


New therapeutic strategy discovered for ovarian cancer
Oncology Nurse Advisor
Researchers have identified a new therapeutic target for a particularly aggressive form of ovarian cancer (ovarian clear cell carcinoma), paving the way for what could be the first effective targeted therapy of its kind for the disease. Their findings were published in Nature Medicine. The researchers observed that ARID1A-mutated ovarian cancers are sensitive to EZH2 inhibition. Most exciting of all, EZH2 inhibition caused the regression of ovarian tumors with mutated ARID1A, while having minimal effects on the growth of ovarian tumor with normal or unmutated ARID1A in experimental models.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.

Antiangiogenic agents in ovarian cancer
OncLive (Video interview)
Bevacizumab is an antiangiogenic agent that exploits the tumor microvasculature, explains Robert A. Burger, MD. As long as there is no disease progression or unacceptable toxicities, and patients are willing to receive it, bevacizumab therapy should be continued indefinitely, states James Tate Thigpen, MD. Burger notes that there are studies in non-gynecologic tumors, such as colon cancer, that have continued antiangiogenic therapy beyond disease progression and demonstrated survival advantage in the next line of therapy.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Morcellation foe presses on despite return of cancer
Medscape (Free login required)
The anesthesiologist whose occult uterine cancer was upstaged as a result of laparoscopic power morcellation during a hysterectomy remains a staunch patient-safety advocate despite the recent return of her disease. Her high-profile case already has spurred a retreat from the use of the tissue-shredding devices, abetted by strong warnings from the US Food and Drug Administration (FDA) about the risk of dispersing occult cancer in abdominal cavities. However, she and her husband, Hooman Noorchashm, MD, PhD, hope to persuade gynecologic surgeons to abandon the technology entirely.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


In cancer wars, it's doctors vs. hospitals
MedPage Today
Colliding federal policies are fomenting a nasty money war that's pitting community oncologists trying to treat patients in less expensive clinic settings against hospitals trying to woo patients in through costlier emergency departments. In Albuquerque, Barbara McAneny, MD, says evidence of this fight came in an orange postcard a local hospital mass-mailed to area homes. And Tracey Weisberg, MD, of Southern Maine's New England Cancer Specialists is in the middle what she calls "a horrible" fight over a similar issue.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Improvements in cancer survival better for younger patients
Survival has improved for patients with cancers of the colon or rectum, breast, prostate, lung, and liver, and those improvements were better among younger patients, according to a study published online by JAMA Oncology. Cancer is a leading cause of death in the United States and many other countries although progress has been made during the past few decades with significant advances in surgery, radiotherapy, chemotherapy, and targeted therapies. Those improvements, along with better cancer screening and diagnosis, have led to steady improvements in survival, according to the study background.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Uncover Hereditary Cancer Risk for Your Patients
The average OB/GYN has 400 patients who meet criteria for further evaluation of hereditary cancer syndrome. Learn how to identify high-risk patients.
Advertise here!

To find out how to feature your company in the SGO News Brief and other advertising opportunities, Contact Geoffrey Forneret at 469-420-2629.


Reshaping tumor cells may be new way to treat breast cancer
Medical News Today
Writing in the journal Molecular Systems Biology, researchers from the Institute of Cancer Research in London, U.K., describe how they used robotic microscopy and mathematical algorithms — not unlike the algorithms Facebook uses for facial recognition — to assess shape and contextual features of hundreds of thousands of cancer cells. The study highlights the fact that the body's natural defenses are constantly battling against cancer cells, and there are numerous strategies on both sides of the fight. Health wins when the balance tips one way — disease wins when it tips the other way.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Visit the SGO Women's Cancer News archive page.

More evidence breast cancer and prostate cancer cluster in families
Women with close male relatives with prostate cancer are more likely to be diagnosed with breast cancer, a new study confirms. These findings, from the large Women's Health Initiative, reinforce the results of a 1994 study in the Journal of the National Cancer Institute, the authors write. “This is not the first study to examine this relationship, but it is one of the larger to date, if not the largest study,” said lead author Jennifer L. Beebe-Dimmer of Karmanos Cancer Institute in Detroit.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news

Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

March 4, 2015
Feb. 25, 2015
Feb. 18, 2015
Feb. 11, 2015

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063